Cancer Research Annual Meeting 2010  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rainis, L.
Right arrow Articles by Izraeli, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rainis, L.
Right arrow Articles by Izraeli, S.
[Cancer Research 65, 7596-7602, September 1, 2005]
© 2005 American Association for Cancer Research


Molecular Biology, Pathobiology and Genetics

The Proto-Oncogene ERG in Megakaryoblastic Leukemias

Liat Rainis1,2, Tsutomu Toki3, John E. Pimanda4, Ester Rosenthal1, Keren Machol1,2, Sabine Strehl5, Berthold Göttgens4, Etsuro Ito3 and Shai Izraeli1,2,5

1 Department of Pediatric Hematology-Oncology, Safra Children's Hospital and Hematology Institute, Sheba Cancer Research Center, Sheba Medical Center, Tel-Hashomer, Israel; 2 Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 3 Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan; 4 Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom; and 5 Children's Cancer Research Institute, Vienna, Austria

Requests for reprints: Shai Izraeli, Research Section, Department of Pediatric Hemato-Oncology, Sheba Medical Center, 52621 Tel-Hashomer, Israel. Phone: 972-3-530-3037; Fax: 972-3-530-3031; E-mail: sizraeli{at}post.tau.ac.il.

Aneuploidy is one of the hallmarks of cancer. Acquired additions of chromosome 21 are a common finding in leukemias, suggesting a contributory role to leukemogenesis. About 10% of patients with a germ line trisomy 21 (Down syndrome) are born with transient megakaryoblastic leukemia. We and others have shown acquired mutations in the X chromosome gene GATA1 in all these cases. The gene or genes on chromosome 21 whose overexpression promote the megakaryoblastic phenotype are presently unknown. We propose that ERG, an Ets transcription factor situated on chromosome 21, is one such candidate. We show that ERG is expressed in hematopoietic stem cells, megakaryoblastic cell lines, and in primary leukemic cells from Down syndrome patients. ERG expression is induced upon megakaryocytic differentiation of the erythroleukemia cell lines K562 and UT-7, and forced expression of ERG in K562 cells induces erythroid to megakaryoblastic phenotypic switch. We also show that ERG activates the gpIb megakaryocytic promoter and binds the gpIIb promoter in vivo. Furthermore, both ERG and ETS2 bind in vivo the hematopoietic enhancer of SCL/TAL1, a key regulator of hematopoietic stem cell and megakaryocytic development. We propose that trisomy 21 facilitates the occurrence of megakaryoblastic leukemias through a shift toward the megakaryoblastic lineage caused by the excess expression of ERG, and possibly by other chromosome 21 genes, such as RUNX1 and ETS2, in hematopoietic progenitor cells, coupled with a differentiation arrest caused by the acquisition of mutations in GATA1.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
J. O. Korbel, T. Tirosh-Wagner, A. E. Urban, X.-N. Chen, M. Kasowski, L. Dai, F. Grubert, C. Erdman, M. C. Gao, K. Lange, et al.
The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies
PNAS, July 21, 2009; 106(29): 12031 - 12036.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Salek-Ardakani, G. Smooha, J. de Boer, N. J. Sebire, M. Morrow, L. Rainis, S. Lee, O. Williams, S. Izraeli, and H. J.M. Brady
ERG Is a Megakaryocytic Oncogene
Cancer Res., June 1, 2009; 69(11): 4665 - 4673.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
I. Ganmore, G. Smooha, and S. Izraeli
Constitutional aneuploidy and cancer predisposition
Hum. Mol. Genet., April 15, 2009; 18(R1): R84 - R93.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. J. Stankiewicz and J. D. Crispino
ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells
Blood, April 2, 2009; 113(14): 3337 - 3347.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Malinge, S. Izraeli, and J. D. Crispino
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome
Blood, March 19, 2009; 113(12): 2619 - 2628.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Izraeli
Trisomy 21 tilts the balance
Blood, December 1, 2008; 112(12): 4361 - 4362.
[Full Text] [PDF]


Home page
BloodHome page
O. Tunstall-Pedoe, A. Roy, A. Karadimitris, J. de la Fuente, N. M. Fisk, P. Bennett, A. Norton, P. Vyas, and I. Roberts
Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations
Blood, December 1, 2008; 112(12): 4507 - 4511.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. M. Birdsey, N. H. Dryden, V. Amsellem, F. Gebhardt, K. Sahnan, D. O. Haskard, E. Dejana, J. C. Mason, and A. M. Randi
Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin
Blood, April 1, 2008; 111(7): 3498 - 3506.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Kirsammer, S. Jilani, H. Liu, E. Davis, S. Gurbuxani, M. M. Le Beau, and J. D. Crispino
Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome
Blood, January 15, 2008; 111(2): 767 - 775.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Y. I. Chan, G. A. Follows, G. Lacaud, J. E. Pimanda, J.-R. Landry, S. Kinston, K. Knezevic, S. Piltz, I. J. Donaldson, L. Gambardella, et al.
The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype
Blood, March 1, 2007; 109(5): 1908 - 1916.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. E. Pimanda, L. Silberstein, M. Dominici, B. Dekel, M. Bowen, S. Oldham, A. Kallianpur, S. J. Brandt, D. Tannahill, B. Gottgens, et al.
Transcriptional Link between Blood and Bone: the Stem Cell Leukemia Gene and Its +19 Stem Cell Enhancer Are Active in Bone Cells.
Mol. Cell. Biol., April 1, 2006; 26(7): 2615 - 2625.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J.-P. Bourquin, A. Subramanian, C. Langebrake, D. Reinhardt, O. Bernard, P. Ballerini, A. Baruchel, H. Cave, N. Dastugue, H. Hasle, et al.
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling
PNAS, February 28, 2006; 103(9): 3339 - 3344.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.